These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36400591)

  • 21. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis.
    Mehrabi Nejad MM; Shobeiri P; Dehghanbanadaki H; Tabary M; Aryannejad A; Haji Ghadery A; Shabani M; Moosaie F; SeyedAlinaghi S; Rezaei N
    Virol J; 2022 Aug; 19(1):132. PubMed ID: 35941646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
    Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
    Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
    J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody response to 2- and 3-dose SARS-CoV-2 mRNA vaccination in pediatric and adolescent kidney transplant recipients.
    Crane C; Phebus E; Ingulli E
    Pediatr Nephrol; 2023 Feb; 38(2):611-614. PubMed ID: 35759003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
    Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
    J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients.
    Hamaya T; Hatakeyama S; Yoneyama T; Tobisawa Y; Kodama H; Fujita T; Murakami R; Fujita N; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Saitoh H; Narumi S; Tomita H; Ohyama C
    Sci Rep; 2022 Apr; 12(1):5876. PubMed ID: 35393481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody, cell-mediated response and infection susceptibility in allogeneic hematopoietic stem cell recipients after COVID-19 mRNA vaccination.
    Pizzano U; Facchin G; Marcon C; Fabris M; Battista ML; Cerno M; Geromin A; Pucillo M; Petruzzellis G; Vianello G; Battaglia G; Peressutti R; Grillone L; Tascini C; Curcio F; Fanin R; Patriarca F
    Transpl Infect Dis; 2023 Apr; 25(2):e14003. PubMed ID: 36748718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients.
    Guarino M; Esposito I; Portella G; Cossiga V; Loperto I; Tortora R; Cennamo M; Capasso M; Terracciano D; Galeota Lanza A; Di Somma S; Picciotto FP; Morisco F;
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1534-1541.e4. PubMed ID: 35066136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients.
    Ruether DF; Schaub GM; Duengelhoef PM; Haag F; Brehm TT; Fathi A; Wehmeyer M; Jahnke-Triankowski J; Mayer L; Hoffmann A; Fischer L; Addo MM; Lütgehetmann M; Lohse AW; Schulze Zur Wiesch J; Sterneck M
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):162-172.e9. PubMed ID: 34509643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune response to third SARS-CoV-2 vaccination in seronegative kidney transplant recipients: Possible improvement by mycophenolate mofetil reduction.
    Kantauskaite M; Müller L; Hillebrandt J; Lamberti J; Fischer S; Kolb T; Ivens K; Koch M; Andree M; Lübke N; Schmitz M; Luedde T; Orth HM; Feldt T; Schaal H; Adams O; Schmidt C; Kittel M; Königshausen E; Rump LC; Timm J; Stegbauer J
    Clin Transplant; 2022 Nov; 36(11):e14790. PubMed ID: 35997031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipients.
    Meunier L; Sanavio M; Dumortier J; Meszaros M; Faure S; Ursic Bedoya J; Echenne M; Boillot O; Debourdeau A; Pageaux GP
    Liver Int; 2022 Aug; 42(8):1872-1878. PubMed ID: 35338550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early humoral immune response to two doses of severe acute respiratory syndrome coronavirus 2 vaccine in a diverse group of solid organ transplant candidates and recipients.
    Huang HJ; Yi SG; Mobley CM; Saharia A; Bhimaraj A; Moore LW; Kloc M; Adrogue HE; Graviss EA; Nguyen DT; Eagar TN; Jones SL; Ankoma-Sey V; MacGillivray TE; Knight RJ; Gaber AO; Ghobrial RM
    Clin Transplant; 2022 May; 36(5):e14600. PubMed ID: 35083796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of SARS-CoV-2 vaccine with immunosuppressive agents.
    Kamei K; Ogura M; Sato M; Nishi K; Shoji K; Funaki T; Ogimi C; Ito S
    Pediatr Int; 2022 Jan; 64(1):e15331. PubMed ID: 36331234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 Vaccines in Pancreatic Transplant Recipients: A Single-Center Observative Study.
    Matejak-Górska M; Zielonka M; Górska H; Durlik M
    Transplant Proc; 2022 May; 54(4):925-929. PubMed ID: 35437149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of a third dose of anti-SARS-CoV-2 BNT16b2 vaccine in liver transplant recipients.
    Toniutto P; Cussigh A; Cmet S; Bitetto D; Fornasiere E; Fumolo E; Fabris M; D'Aurizio F; Fabris C; Grillone L; Sartor A; Curcio F; Falleti E
    Liver Int; 2023 Feb; 43(2):452-461. PubMed ID: 35661561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
    Thuluvath PJ; Robarts P; Chauhan M
    J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients.
    Tunbridge M; Perkins GB; Singer J; Salehi T; Ying T; Grubor-Bauk B; Barry S; Sim B; Hissaria P; Chadban SJ; Coates PT
    Trials; 2022 Sep; 23(1):780. PubMed ID: 36109788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of two-dose SARS-CoV-2 vaccination
    Chen CC; Huang YJ; Lai MJ; Lin MH; Lin WC; Lin HY; Lin YC; Huang YT; Lee YF; Tsai MK; Lee CY
    Front Immunol; 2022; 13():951576. PubMed ID: 36189313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: A systematic review.
    Akyol M; Çevik E; Ucku D; Tanrıöver C; Afşar B; Kanbay A; Covic A; Ortiz A; Basile C; Kanbay M
    Tuberk Toraks; 2021 Dec; 69(4):547-560. PubMed ID: 34957748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
    Erol Ç; Yanık Yalçın T; Sarı N; Bayraktar N; Ayvazoğlu Soy E; Yavuz Çolak M; Azap Ö; Arslan H; Haberal M
    Exp Clin Transplant; 2021 Dec; 19(12):1334-1340. PubMed ID: 34951350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.